Ever since the attempt to sequence the human genome was conceptualized, it was well known that proteins play a role in health and disease. With the first biologics as protein therapies in the form of Insulins approved in 1982, the race for original biologics has turned competitive. But, that also spiraled debates on costs, prompting regulators to consider similar copies i.e. Biosimilars for therapeutics across various clinical indications in oncology, autoimmunity, cardiovascular-metabolic... Read more